Then, in February 2025, FDA removed semaglutide from its shortage list, giving some pharmacies, called 503A pharmacies, until April 22, 2025, to stop dispensing exact copies of semaglutide, and others, so-called 503B pharmacies, until May 22, 2025
Regulates the hormones that act on fat cells
Direct medical costs of obesity in the United States and the most populous states
10 mg/mL concentration Higher concentration vials are less common but increasingly used by pharmacies that want to minimize injection volumes, especially at higher doses
If approved, it could redefine the standard of care for millions worldwide
The glucagon receptor in retatrutide directly stimulates hepatic fat oxidation, creating a specific mechanism for liver fat reduction that dual agonists lack